Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20408716 | 0.99 | BRAF (0.52) | BRAFCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL912842 | 0.96 | BRAF (0.56) | BRAFCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL29796692 | 0.96 | BRAF (0.56) | BRAFCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL413368 | 0.91 | CYP3A4 (0.62) | BRAFCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1443283 | 0.89 | CYP3A4 (0.51) | BRAFCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL913372 | 0.86 | BRAF (0.55) | BRAFCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1437566 | 0.86 | FABP4 (0.51) | BRAFCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL20408784 | 0.83 | BRAF (0.54) | BRAFCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL20399233 | 0.82 | FABP4 (0.51) | BRAFCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL20399212 | 0.82 | BRAF (0.46) | BRAFCYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110291089-B | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing liver cell death | 海帕瑞吉尼克斯股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11040027-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2021-06-22 | — | — | US | disclosed |
| US-11040027-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2021-06-22 | — | — | US | disclosed |
| WO-2018134254-A1 | PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040027-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, HNF4A, HGF | BRAF 113/4885CYP3A4 1499/4885CYP2C9 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.